摘要
纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor-1,PAI-1)属于丝氨酸蛋白酶抑制剂超家族成员之一,是发挥多种细胞效应的多效性因子,许多细胞效应潜在地与肿瘤的发生发展有关,包括细胞迁移、侵袭、黏附和血管生成,为潜在的治疗方法和新药物的开发奠定了基础。PAI-1在许多类型的癌症中过表达被发现是预后不良的一个指标。研究表明,PAI-1可作为潜在预测性生物标志物和治疗靶点应用于膀胱癌的临床诊疗中。本文就PAI-1在膀胱癌中的功能和机制进行探讨。
Plasminogen activator inhibitor-1(PAI-1),a member of the serine protease inhibitor superfamily,is a pleiotropic factor that plays a variety of cellular effects,many of which are potentially related to the occurrence and development of tumors,including cell migration,invasion,adhesion,and angiogenesis,laying the foundation for potential therapeutics and the development of new drugs.PAI-1 over-expression in many types of cancers has been found to be an indicator of poor prognosis.Studies suggest that PAI-1 can be used as a potential predictive biomarker and therapeutic target in the clinical treatment of bladder cancer.In this paper,the function and mechanism of PAI-1 in bladder cancer are discussed.
作者
刘帅妹
侯彦强
Liu Shuaimei;Hou Yanqiang(Department of Laboratory,Songjiang Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 201600,China)
出处
《国际医药卫生导报》
2025年第14期2310-2313,共4页
International Medicine and Health Guidance News
基金
上海市卫生健康系统重点学科(2024ZDXK0065)
上海市松江区医学重点学科(24SJYXZDA06)。
